RCSI, Science Foundation Ireland (SFI) and Shire, in partnership with the Irish Haemophilia Society, jointly announced a major new €4 million, patient-orientated study entitled “The Irish Personalised Approach to the Treatment of Haemophilia (iPATH)” on Monday 4 December. Pictured at the launch were (l-r) Ms Noelle Costelloe, Programme Manager for iPATH and Irish Centre for Vascular Biology, RCSI; Dr Peter Turecek, Senior Director, Global Medical Affairs, Shire; Mr Brian O’Mahony, Chief Executive of the Irish Haemophilia Society; Professor Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Adviser to the Government of Ireland; Professor James O’ Donnell, Director of the Irish Centre for Vascular Biology, RCSI and Consultant Haematologist in the National Coagulation Centre in St James’ Hospital, Dublin; Dr Roger Preston, Principal Investigator iPATH, Irish Centre for Vascular Biology, RCSI; Professor Padraic Fallon Principal Investigator iPATH, Professor of Translational Immunology, TCD; Dr John Gormley, Principal Investigator iPATH, Discipline of Physiotherapy, School of Medicine TCD; Dr Michelle Lavin, Principal Investigator iPATH, Clinical Research Fellow, Irish Centre for Vascular Biology, RCSI and St. James’s Hospital Dublin